- Home
- INCR vs MREO Comparison
INCR vs MREO Comparison
Compare INCR & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCR | MREO |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 52.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | INCR | MREO |
|---|---|---|
| Price | $0.83 | $0.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 39.5K | ★ 1.5M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $69.54 | $5,184.20 |
| Revenue Next Year | $41.75 | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.20 |
| 52 Week High | $1.77 | $2.94 |
Technical Indicators
Market Signals| Indicator | INCR | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 36.41 |
| Support Level | $0.86 | $0.20 |
| Resistance Level | $0.93 | $0.36 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 77.33 | 25.24 |
Price Performance
Historical ComparisonAbout INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).